Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806507 | 0.89 | NPSR1 (0.40) | L3MBTL1GNRHRNPSR1MAPK1LMNA | |
| SCHEMBL1805130 | 0.87 | L3MBTL1 (0.39) | L3MBTL1GNRHRNPSR1MAPK1LMNA | |
| SCHEMBL11971975 | 0.86 | GNRHR (0.41) | GNRHRNPSR1MAPK1LMNAPOLB | |
| SCHEMBL11972749 | 0.83 | TSHR (0.43) | NPSR1MAPK1LMNAPOLBPKM | |
| SCHEMBL1811067 | 0.81 | GNRHR (0.38) | L3MBTL1GNRHRNPSR1MAPK1LMNA | |
| SCHEMBL1805095 | 0.81 | NPSR1 (0.39) | NPSR1MAPK1LMNAPOLBPKM | |
| SCHEMBL1803399 | 0.81 | ALDH1A1 (0.45) | MAPK1LMNAPOLBMAPTTSHR | |
| SCHEMBL1809873 | 0.80 | KDM4E (0.43) | L3MBTL1NPSR1LMNAPOLBPKM | |
| SCHEMBL1804786 | 0.79 | LMNA (0.40) | GNRHRNPSR1MAPK1LMNAPOLB | |
| SCHEMBL1808960 | 0.79 | OPRL1 (0.42) | NPSR1MAPK1TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501704-B1 | Spiropiperidine compounds as oral-1 receptor antagagonisten | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2501704-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120214784-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2011060217-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214784-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OPRL1, ORMDL3, OGFRL1 | L3MBTL1 3321/4885GNRHR 203/4885NPSR1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.